Esperas Pharma Inc. Report issue

For profit Phase 2
Founded: Montreal Canada (2015)
Status: Defunct (2021)

Organization Overview

First Clinical Trial
2016
NCT02632448
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2016

Timeline

NOW
  • Now

Active Ingredients

Drugs in Phase 2 Trials (2)

gemcitabine (gemzar) (1 trial)

ly2880070 (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Breast Neoplasms (Phase 2)

Endometrial Neoplasms (Phase 2)

Neoplasm Metastasis (Phase 2)

Neoplasms (Phase 2)

Pancreatic Neoplasms (Phase 2)

Sarcoma (Phase 2)

Triple Negative Breast Neoplasms (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 1
  • # of Trial APIs: 2